Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Dyadic International today. The company’s shares closed yesterday at $1.18.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Hewitt is an analyst with an average return of -0.4% and a 44.82% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Ligand Pharma, Repligen, and MaxCyte.
The analyst consensus on Dyadic International is currently a Moderate Buy rating.
DYAI market cap is currently $42.7M and has a P/E ratio of -6.33.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DYAI in relation to earlier this year.
Read More on DYAI:
Disclaimer & DisclosureReport an Issue
- Dyadic International announces achievement of milestone payments
- Dyadic International Amends Security Agreement with CEO Trust
- Craig-Hallum bullish on Dyadic International, initiates with a Buy
- Dyadic International initiated with a Buy at Craig-Hallum
- Dyadic International’s Earnings Call Highlights Growth and Challenges
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/Businessman%20touching%20the%20brain%20working%20of%20Artificial%20Intelligence%20(AI)%20Automation%20by%20Suttiphong%20Chandaeng%20via%20Shutterstock.jpg)
/EV%20in%20showroom%20by%20Robert%20Way%20via%20Shutterstock.jpg)
